Phio Pharmaceuticals
Company Details
Status: Public
Employees: 1-10
Location:
Marlborough, Massachusetts, United States
Type:
sample
Technology:
sample
sample
sample
sample
sample
sample
sample
About: Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Phio was co-founded by Nobel Laureate Craig Mello, who was awarded the Nobel prize in 2006 for his discovery of RNAi, which has broad therapeutic applications. Our founders opened up a whole new field of biology when they discovered RNAi, and we continue their pioneering efforts today through our work with INTASYL. We’re committed to discovering and developing innovative cancer treatments for patients, creating new pathways for a cancer-free future.
For additional information, visit the Company's website, www.phiopharma.com.
#INTASYL #siRNA #RNAi #Phio #immunooncology
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Phio Pharmaceuticals | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.